Xarelto more effective than warfarin for stroke prevention in Asian AF
By John Fox
Friday, May 2, 2014
HONG KONG The oral anticoagulant Xarelto (rivaroxaban, Johnson & Johnson) is more effective than warfarin for preventing stroke and intracranial hemorrhage (ICH), particularly in Asian patients with atrial fibrillation (AF), Chinese University of Hong Kong (CUHK) scientists have reported. Stroke is the leading cause of death in China, where it kills more than 1.5 million people each year. In Hong Kong, more than 20,000 stroke patients are admitted to hospital for treatment each year and more than 3,000 die, with many of the survivors being disabled. According to a recent CUHK study presented during the 14th Asian Oceanian Congress of Neurology in Macao, China, in March, AF has become one of the leading stroke causes in Hong Kong.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.